Candidate Program Cand Prog
Indication Target Ind Target
Discovery HIT I.D. Discov HIT I.D.
Phase 1 HIT to Lead Ph 1 HIT-Lead
Phase 2 Lead Optimization Ph 2 Lead Opt
Pivotal Trial IND Enabling Pivotal IND
OKI-179
NRAS Melanoma Combo w/Binimetinib*
OKI-179
NRAS Melanoma Combo w/Binimetinib*
Nautilus Trial
Class I HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

*Supply agreement with Pfizer logo; OnKure retains 100% commercialization rights

Discovery

Candidate Program Cand Prog
Indication Target Ind Target
Discovery HIT I.D. Discov HIT I.D.
Phase 1 HIT to Lead Ph 1 HIT-Lead
Phase 2 Lead Optimization Ph 2 Lead Opt
Pivotal Trial IND Enabling Pivotal IND
ONK-001
Kinase
ONK-001
Kinase
ONK-002
Kinase
ONK-002
Kinase
ONK-003
Kinase
ONK-003
Kinase
ONK-004
Kinase
ONK-004
Kinase
ONK-005
Non-Kinase Target
ONK-005
Non-Kinase Target
ONK-006
Non-Kinase Target
ONK-006
Non-Kinase Target
ONK-007
Degrader Target
ONK-007
Degrader Target
ONK-008
Degrader Target
ONK-008
Degrader Target